The generic name of Dayuton Bevacizumab is Bevacizumab Injection, which is dedicated to the treatment of advanced non-small cell lung cancer and metastatic colorectal cancer, etc. Bevacizumab Injection is usually indicated for the treatment of advanced non-small cell lung cancer and metastatic colorectal cancer. It can work by inhibiting the biological activity of human vascular endothelial growth factor, which targets vascular permeability factor. It can reduce tumor angiogenesis and inhibit the progression of metastasis. Continuous treatment with Bevacizumab Injection is usually recommended clinically until disease progression or intolerable toxicity occurs. The main adverse reactions to bevacizumab injection are bleeding, hypertension, gastrointestinal perforation, and proteinuria. If a serious adverse reaction occurs, the drug should be discontinued immediately and symptomatic treatment should be instituted. It is recommended that patients treated with Bevacizumab Injection should be advised to increase or decrease the dose and discontinue the drug under the guidance and advice of a physician.